In Brief: Genzyme Carticel
This article was originally published in The Gray Sheet
Genzyme Carticel: Firm's Tissue Repair division receives approvable letter from FDA indicating that its biologics license application for its cartilage replacement service is safe and effective for repair of clinically significant symptomatic focal defects of the femoral condyle (knee). Final approval requirements outlined by FDA in the June 19 letter, including manufacturing validation and finalization of product labeling and post-marketing study protocols, are expected to be addressed by late July or early August, Genzyme says. FDA's Orthopedic and Rehabilitation Devices Panel recommended at a March meeting that Genzyme's proposed postmarket study include a control group and randomization of both patients and physicians ("The Gray Sheet" March 10, p. 6)...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.